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Cushing’s disease (CD) in a stricter sense derives from pathologic adrenocorticotropic hormone (ACTH) secretion
usually triggered by micro- or macroadenoma of the pituitary gland. It is, thus, a form of secondary hypercortisolism.
In contrast, Cushing’s syndrome (CS) describes the complexity of clinical consequences triggered by excessive cortisol
blood levels over extended periods of time irrespective of their origin. CS is a rare disease according to the European
orphan regulation affecting not more than 5/10,000 persons in Europe. CD most commonly affects adults aged 20–50
years with a marked female preponderance (1:5 ratio of male vs. female). Patient presentation and clinical symptoms
substantially vary depending on duration and plasma levels of cortisol. In 80% of cases CS is ACTH-dependent
and in 20% of cases it is ACTH-independent, respectively. Endogenous CS usually is a result of a pituitary tumor.
Clinical manifestation of CS, apart from corticotropin-releasing hormone (CRH-), ACTH-, and cortisol-producing (malign
and benign) tumors may also be by exogenous glucocorticoid intake. Diagnosis of hypercortisolism (irrespective of
its origin) comprises the following: Complete blood count including serum electrolytes, blood sugar etc., urinary free
cortisol (UFC) from 24 h-urine sampling and circadian profile of plasma cortisol, plasma ACTH, dehydroepiandrosterone,
testosterone itself, and urine steroid profile, Low-Dose-Dexamethasone-Test, High-Dose-Dexamethasone-Test,
after endocrine diagnostic tests: magnetic resonance imaging (MRI), ultra-sound, computer tomography (CT) and
other localization diagnostics. First-line therapy is trans-sphenoidal surgery (TSS) of the pituitary adenoma (in case
of ACTH-producing tumors). In patients not amenable for surgery radiotherapy remains an option. Pharmacological
therapy applies when these two options are not amenable or refused. In cases when pharmacological therapy becomes
necessary, Pasireotide should be used in first-line in CD. CS patients are at an overall 4-fold higher mortality rate than
age- and gender-matched subjects in the general population. The following article describes the most prominent
substances used for clinical management of CS and gives a systematic overview of safety profiles, pharmacokinetic
(PK)-parameters, and regulatory framework.
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Both, Cushing’s disease (CD) and Cushing’s syndrome
(CS), are rare diseases characterized by high cortisol
blood levels and impairment of circadian oscillation [1].
CD derives from pathologic adrenocorticotropic hormone
(ACTH) secretion usually triggered by micro- or macro-
adenoma of the pituitary gland [2]. It is, thus, a form of
secondary hypercortisolism. In contrast, CS describes the
complexity of clinical consequences triggered by excessive
cortisol blood levels over extended periods of time
irrespective of their origin [3]. Clinical manifestation* Correspondence: niels.eckstein@bfarm.de
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unless otherwise stated.of CS, apart from corticotropin-releasing hormone
(CRH-), ACTH-, and cortisol-producing (malign and
benign) tumors may also be by exogenous glucocorticoid
intake (Figure 1B). Patient presentation and clinical symp-
toms substantially vary depending on duration and plasma
levels of cortisol. In 80% of cases CS is ACTH-dependent
and in 20% of cases is ACTH-independent, respectively
[4]. Clinical differentiation with respect to the onset of a
certain treatment algorithm is by ACTH dependency and
independency, respectively:
ACTH-dependent
➢ Pituitary adenoma (CD in strict sense) ~ 70% [5]
➢ Ectopic secretion of ACTH by non-pituitary
tumors ~ 15% (i.e. neuroendocrine tumors such asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic overview of the hypothalamic-pituitary-adrenal (HPA) axis. A) Schematic overview of the hypothalamic-pituitary-adrenal
(HPA) axis. Depicted is the physiological hierarchical pathway to cortisol-secretion from the zona fasciculata of the adrenal cortex including negative
feed-back loop. Also shown are the most prominent effects of cortisol. B) Schematic overview of HPA axis in pathologically de-regulated CS-patients.
Pathological condition may lead to CRH, ACTH, and cortisol overproduction and impaired negative feed-back loop. Also shown are most hazardous
clinical side-effects of hypercortisolism and target of cortisol blockade.
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Table 1 Regulatory status of medicines for the treatment of hypercortisolism in alphabetical order
Drug substance
(trade name)






Originally approved with the
following wording:
Not approved any more L02BG01 Tablet Oral
Indication: CS
In some patients < Orimeten > is
indicated for preparation of surgery.
A long-term administration is possible
in case of inoperable patients or in
case of recurrence after incomplete
adrenalectomy. CS may be due to
- Adrenocortical tumors (adenoma
and carcinoma)















Treatment of CS MAA submitted to the EMA2 J02AB02 Tablet Oral
Metyrapone
(Metopirone®)
- As a diagnostic test for ACTH
insufficiency and in the differential
diagnosis of ACTH-dependent CS.
Licensed in Ireland, UK, France
based on national procedures
V04CD01 Capsule Oral





Treatment of CS secondary to
ectopic ACTH secretion
Not yet approved in CS3 G03XB01 Tablet Oral
MAA submitted to EMA
Mitotane
(Lysodren®)
Symptomatic treatment of advanced
(non-resectable, metastatic or recurrent)
adrenal carcinoma
Licensed via central procedure






Second-line treatment of CD in patients
where surgery has failed
Licensed via central procedure
as orphan drug since 2012








Rosiglitazone is used to treat type 2
diabetes mellitus, particularly those
who are overweight. It is used in
addition to diet and exercise
Currently suspended for use in
the European Union, restricted




Off-label in aggressively growing
pituitary macroademomas






Abbreviations: CD, Cushing’s disease; CS, Cushing’s syndrome; EMA, European Medicines Agency; MAA, marketing authorization application; 1If off-label use,
ATC-Code from other indication is depicted; 2in anti-fungal (Nizoral®) indication marketing authorization is suspended in Europe due to hepatotoxicity;
3for abortion, licensing status is varying among European Member States.
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and medullary carcinoma of the thyroid) [6]
➢ Ectopic secretion of CRH by non-hypothalamic
tumors causing pituitary hypersecretion of
ACTH < 1% [7]
➢ Iatrogenic or factitious CS due to administration of
exogenous ACTH< 1%
ACTH-independent➢ Adrenocortical adenomas and carcinomas ~ 20% [8]
➢ Primary pigmented nodular adrenocortical
disease < 1% [9]
➢ Bilateral ACTH-independent adrenal
hyperplasia < 1% [10]
However, systemic treatment options are limited and
clinical evidence of these options is scarce (with Pasireotide
Figure 2 Chemical structures of medicinal products used for systemic treatment of CS in alphabetical order.
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pharmacological treatment options are reflected in Table 1.
Chemical structures of medicines used in-label and off-
label are depicted in Figure 2. According to the European
Community Register [11] (accessed on March 12th, 2014)
the medicinal products were granted an orphan desig-
nation in the context of CS.
Etiology and symptoms
CS is a rare disease according to the European orphan
regulation [12] affecting not more than 5/10,000 persons
in Europe. CS is a heterogeneous disorder that arises from
multiple causes and has a broad spectrum of eventually
fatal co-morbidities such as diabetes and hypertension.
ERCUSYN is the synonym for The European Registry
on Cushing’s Syndrome. In a startling publication from
2011 Valassi et al. [13] describe the baseline demographic
and clinical characteristics from:
1. a prospective cohort of 398 CS patients who were
recruited from October 1st 2008 (when the database
was opened) to October 31st 2010, and2. a retrospectively collected cohort of 83 patients
diagnosed of CS since January 1st 2000 with yearly
updates.
This patient population consisted of:
➢ 317 (66%) patients suffering from CD
➢ 130 (27%) patients who had adrenal-CS
➢ 24 (5%) patients who had ectopic-CS
➢ 10 (2%) patients classified as having other forms
of CS
CS comprises numerous general and endocrine symp-
toms and side effects some of which might be entailed
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➢ osteoporosis and eventually fractures
➢ muscle weakness
Thus, adverse events are indistinguishable from long-
term (sometimes unavoidable) glucocorticoid therapy.








➢ clotting disorders (eventually even
hypercoagulability [14].
Especially weight gain, diabetes, and hypertension are
hazardous for patients due to two reasons:
1) They are (apart from infections) responsible for a
50% mortality within the first 5 years after diagnosis
mainly due to cardiovascular events [15].
2) These symptoms usually are diagnosed as metabolic
syndrome, thereby delaying time to diagnosis [16].
According to current data time to diagnosis after the
first symptoms is 6.0 years in mean [17]. In this regard,
un-specificity of symptoms is highly problematic alike
the slow-progressive nature of the disease [18]. However,
months or even years of un-diagnosed CS may cause
irreversible organ damage or be fatal due to late-stage
diagnosis of malignant disease (i.e. ectopic ACTH pro-
ducing SCLC). Recovery from the a.m. co-morbidities
occurs, but may be delayed or incomplete. The duration
of chronic hypercortisolism may determine reversibility of
the co-morbidities associated with CD [19]. In addition, CS
side-effects lead to an increased cardiovascular risk, thus,
rendering even timely diagnosed CS a life-threatening dis-
ease, which is also due to infections: 71.4% of the deaths
from CS can be attributed to cardiovascular causes or infec-
tion [20]. Standardized mortality ratios (SMR) in Cushing
patients throughout the Ntali-study were statistically
significantly elevated in the overall analysis (SMR 9.3;
95% CI, 6.2 - 13.4, p < 0.001), as well as in all subgroups
of patients under investigation. Patients with ectopic
CS had the worst outcome with a probability of only
77.6% to survive the next 5 years. A systematic analysis
of mortality studies in patients with CS as a consequence
of an adrenal adenoma was undertaken by Graversen andcolleagues in 2012 [21]. CD patients with persistent
disease after initial surgery had a SMR of 3.73 (95% CI:
2.31 - 6.01), whereas mortality of CD patients with initial
remission did not differ significantly from the general
population (SMR: 1.23 (95% CI: 0.51 - 2.97)). This
study confirms the excess mortality in patients with CD
if remission after initial surgery is not achieved.Epidemiology of Cushing’s syndrome as a rare disease
Approximately 1% of the population use exogenous steroids,
of which 70% experience one or more adverse events [22].
In contrast, a national register in Denmark reported an an-
nual incidence for endogenous CS of two cases per million
people [23]. Endogenous CS is usually (in 70% of cases)
a result of a pituitary tumor. In general, CS is rare: the
reported incidence of endogenous CS worldwide ranges
from 0.7 - 2.4 cases per million per year [24]. CD most
commonly affects adults aged 20 - 50 years with a marked
female preponderance (1:5 ratio of male vs. female). CS
patients are at an overall 4-fold higher mortality rate
than age- and gender-matched subjects in the general
population [25]. When diagnosed the prevalence of co-
morbidities has been reported as follows: 58 – 85% of
patients have hypertension, 32 – 41% obesity, 20 – 47%
diabetes mellitus, 50 – 81% major depression, 31 – 50%
osteoporosis, and 38 – 71% dyslipidemia [19].Lines of treatment
Depending on the cause of these excessive cortisol concen-
trations in the patient’s blood, different treatment modal-
ities are possible in routine patient care. Therapy of choice
is trans-sphenoidal surgery (TSS) of the pituitary adenoma
(in case of ACTH-producing tumors). In patients not
amenable for surgery radiotherapy remains an option.
Thus, primary lines of therapy in CD (i.e. not medication
associated CS) consists of TSS and pituitary irradiation.
TSS is currently the most frequently recommended
treatment except for patients who are poor surgical
candidates, have invasive tumors, or who refuse surgery.
The surgical effectiveness varies depending on expertise
in pituitary surgery and the size and extension of the
anatomic mass. Hypopituitarism is common after TSS
with a range between 13 and 81% [3]. Early remission in
terms of cortisol blood level normalization is achieved
regularly (Figure 1A). Patients who do not achieve nor-
malization with surgery require additional treatment,
usually with radiotherapy and/or medication. If damage
to the surrounding normal pituitary tissue occurs during
surgery, the patient may require lifelong pituitary hormone
replacement. However, an examination of remission and
recurrence rates in long-term follow-up studies reveals that
potentially up to 40% to 50% of patients could require add-
itional treatment [26]. Thus, systemic (medicinal) treatment
Eckstein et al. Orphanet Journal of Rare Diseases 2014, 9:122 Page 6 of 16
http://www.ojrd.com/content/9/1/122of CS may be more important than traditionally thought
(Figure 1B).
Pituitary irradiation is usually reserved for patients
who have tumor remaining after surgery, for patients
who are poor candidates for surgery, and for patients
who do not respond adequately to surgery and/or medi-
cation. The main disadvantages of radiotherapy are that
i) normalization of ACTH secretion may take extended
periods of time (eventually years) to occur demanding
for medication while success of radiation is awaited, and
ii) that patients may develop generalized anterior pituit-
ary insufficiency [27].
Pharmacological therapy applies when these two options
are not amenable or refused. In cases when pharmaco-
logical therapy becomes necessary, Pasireotide should be
used in first-line in ACTH-dependent CS. However, sys-
temic pharmacotherapy of CS often shows – sometimes
dose-limiting – side effects. A systematic overview of
safety profiles is given in Table 2. The source of data
in Table 2 is a systematic recherché in section 4.8 of
currently (March 2014) approved SmPCs of licensed
medicines. In the following sections drugs used in CS
treatment (Figure 2) are referred to in alphabetical
order (as in all Tables and Figures). Molecular inter-
action of the respective drug with cortisol-biosynthesis
is depicted in Figure 3, whereas PK parameters of the
respective substances are listed in Table 3.
Aminoglutethimide
Aminoglutethimide from its molecular mechanism is a
non-selective, non-steroidal aromatase inhibitor. Due
to its non-selective mechanism of action it also inhibits
endogenous cortisol synthesis. Schteingart et al. back in
1966 showed that Aminoglutethimide can alleviate clinical
symptoms of CS in a patient suffering from metastatic
adrenal cancer [37]. However, the same consortium of
authors found one year later that its effect can be over-
ruled by excessive secretion of ACTH [38]. Following a
report of three patients receiving Aminoglutethimide in
combination with Metyrapone, these substances were also
given concomitantly [39]. However, Aminoglutethimide is
marketed no more.
Cabergoline
Two types of receptors are widely expressed at the surface
of pituitary adenoma cells: the somatostatin receptor
subtype 5 (SSTR-5) and the dopamine receptor subtype
2 (D2). As mentioned above, SSTR-5 is occupied by
Pasireotide prevalently compared to other somatostatins.
Dopamine agonists (e.g. bromocriptine, quinagolide, caber-
goline) bind to D2 receptors in the pituitary gland.
In CD corticotroph adenomas mainly express D2 recep-
tors (and SSTR-5). Agonists at these receptors inhibit
ACTH-release in cell culture of corticotroph adenomas.In those in vitro model systems compounds that target
SSTR-5 (like Pasireotide) or D2 (cabergoline) have shown
efficacy in subsets of patients in the clinical setting.
Combination therapy by administration of both types
of compounds yielded promising results.
These clinical reports of enhanced efficacy of combin-
ation therapy with SSTR- and dopamine agonist treatment
(originally initiated for pituitary adenoma therapy in
suppressing growth hormone hypersecretion) lead to the
novel concept of somatostatin-dopamine chimeric mole-
cules, e.g. BIM-23A760 [40]. Preliminary in vitro results
suggest that the affinity to D2 receptors is crucial for in-
hibition of prolactin gene expression and growth hormone
secretion. However, the impact of these substances on CS
in patients remains to be elucidated. In addition, a recent
study showed that D2 receptors are also expressed in the
majority of ectopic ACTH-producing syndrome (EAS)
cases and that cabergoline may decrease cortisol levels in
certain subsets of these patients [41].
Etomidate
Etomidate (just like Ketoconazole) from the chemical
perspective is an imidazole derivative. It was developed in
the sixties as parenteral hypnotic drug [42]. Mechanistic-
ally, Etomidate is a centrally acting γ-aminobutyric acid
type A (GABA-A) receptor agonist [43]. Low serum corti-
sol levels resulting in hypoadrenalism was a randomly
discovered side effect of Etomidate [44]. Etomidate (like
Metyrapone) inhibits the mitochondrial cytochrome
P450 (CYP)-dependent adrenal enzyme 11-β-hydroxylase
that catalyzes the production of cortisol from deoxycorti-
sol, thereby lowering cortisol blood levels within hours
[45]. In a recent systematic review, Preda et al. came to
the conclusion that Etomidate might be of clinical benefit
in last-line therapy under intensive care condition. In the
outpatient endocrinology setting for patients with severe
hypercortisolism there might be a role for Etomidate [30].
Etomidate usually is thought to be efficacious only in hyp-
notic doses, but this appears not to be the case: in the
Preda publication, non-hypnotic doses of only 0.3 mg/kg
were active in lowering cortisol levels.
Glitazones
Glitazones (Thiazolidinedions) like Rosiglitazone or Pioglit-
azone are anti-diabetic insulin sensitizing drugs mediating
their effects via activation of the transcription factor peroxi-
some proliferator-activated receptor γ (PPAR γ). Activation
of PPARγ results in effects on adipogenesis, carbohydrate
and lipid metabolism, inflammation processes, and cell
proliferation [46]. Additionally, PPARγ agonists have been
shown to inhibit the growth of several tumor cells derived
from lung, breast, prostate, and colon cancer tissues
[47-50]. Immunocytochemical PPARγ expression could be
shown in autopsy-derived human pituitary tissue. PPARγ






















Aminoglutethimide XX XX XX X X X X
Cabergoline XX XX X XX XX XX
Etomidate XX XX X XX X X X
Ketoconazole X XX XX XX X XX X
Metyrapone XX X
Mifepristone X X XX
Mitotane XX XX X XX XX XX XX XX
Pasireotide XX XX XX XX XX XX
Rosiglitazone XX XX1 XX X XX






















Aminoglutethimide XX X X X XX
Cabergoline XX X XX X XX
Etomidate XX X XX XX
Ketoconazole XX X XX
Metyrapone XX X X XX X XX
Mifepristone XX X X XX
Mitotane XX XX XX XX X XX XX X XX
Pasireotide XX XX XX XX
Rosiglitazone XX XX XX
Temozolomide XX XX XX XX XX XX XX XX XX XX
Abbreviations: XX, common, very common; X, rare, uncommon, not known; CMR, carcinogenic, mutagenic and toxic for reproductive system; 1Rosiglitatzone was suspended for use in the European Union due to an
increased cardiovascular risk; method of safety profile assessment: between March and June 2014 SmPCs of currently marketed medicinal products were accessed (if not licensed for treatment of CS, then in other



















Figure 3 Endogenous biosynthesis and mechanisms of drug inhibition of cortisol.
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ACTH [51]. However, in pituitary tumors, including
ACTH secreting tumors, PPARγ expression is increased
as compared to the normal pituitary [52]. In rat and
human corticotroph adenoma cell lines Rosiglitazone
decreased tumor cell growth, increased apoptosis, and
lowered ACTH secretion by inhibiting mRNA expression
of its precursor-protein pro-opiomelanocortin (POMC).
PPARγ has furthermore been shown to act as tumor sup-
pressor gene in animals [53,54]. It was hypothesized that
glitazones might be useful in treating corticotroph pitu-
itary adenomas by inhibiting ACTH synthesis and se-
cretion and tumor growth. Subsequently, clinical studies
investigating the role of glitazones in the treatment of CD
were conducted:
In one study, 14 patients with active CD (7 untreated and
7 after unsuccessful surgery) were treated with 8 – 16 mg
of Rosiglitazone for 1 – 7 months [55]. In six patients, 24-
hour urinary free cortisol (UFC) was significantly lowered
and two of them showed clinical improvement at 7-month
follow-up. However, after 10 month cortisol levels increasedand clinical signs relapsed [56]. Pre-operative Rosiglitazone
treatment (8 mg/day) of two patients with pituitary-
dependent CS lowered cortisol levels in the 24-hour
urine and lead to clinical improvement [57]. In a study
of 10 patients, four prior to surgery, four following
relapse after surgery, and two immediately after failed
surgery treated with 4 – 16 mg of Rosiglitazone for 1 –
8 months, no consistent reductions in UFC levels were
found. Only 3 of 10 patients had normalized urinary
cortisol levels up to 8 months [58]. Side effects reported
included edema, weight gain, somnolence, and increased
hirsutism. Although most studies used Rosiglitazone, one
study with Pioglitazone is available [59]. In none of the
five patients with CD treated with 45 mg Pioglitazone
for 30 days any UFC responses were observed. Taken
together, glitazone treatment failed to reproduce the
effects seen in vitro and in animal studies. Only Rosigli-
tazone could be shown to be effective at least in a small
subset of patients. However, Rosiglitazone is currently
suspended in the European Union due to an increased
cardiovascular risk.
Table 3 Clinical pharmacokinetic profiles of medicines used for the treatment of hypercortisolism
Aminoglutethimide Cabergoline Etomidate Ketoconazole Metyrapone
Trade name;
sponsoring company
Orimeten; Novartis Dostinex; Pfizer Hypnomidate; Janssen-Cilag Nizoral; Janssen-Cilag Metopirone; HRA Pharma
European birth date January 18, 1984 June 24, 2002 October 27, 1978 July 20, 1981 April 1, 1979
Cancer indication Metastatic breast cancer No No No No
Cmax (μg/mL) 5.91 37 ± 8 pg/mL N/A 3.5 3.72
tmax (h) 1.0 - 4.0 0.5 – 4.0 N/A 1.0 - 2.0 1.0




With food and water No significant food effect N/A Maximal absorption with food Recommended with






N/A N/A3 [28] 4.5 N/A N/A
Major metabolites N-acetylaminoglutethimide
(N-hydroxylaminoglutethimide
**if enzyme induction occurs)
6-Allyl-8-β-carboxy-ergoline N/A Main metabolism is by oxidation
and cleavage of the imidazole-
and piperazine-ring systems by
hepatic microsomal enzymes.
Metyrapol, an active alcohol
metabolite, similar potency in
inhibiting adrenal 11-β-hydroxylase
Plasma half-life (h) 12.5 ± 1.6 63 - 69 3 - 5 biphasic 2/8 20 - 26 minutes
intravenous, ~2 h oral
Plasma protein
binding (%)





C13H16N2O2 (232.3) C26H37N5O2 (451.6) C14H16N2O2 (244.3) C26H28Cl2N4O4 (531.4) C14H14N2O (226.3)




Dopamine receptor agonist Inhibits cortisol synthesis by
inhibiting CYP11B1, and
cytochrome P450scc [29]













2 - 3 × 250 mg adrenocortical-
carcinoma: 2 - 4 × 250 mg ectopic
ACTH-syndrome: 4 - 7 × 250 mg
Initiation of therapy: 0.25 mg
twice a week. Dosage may be
increased by 0.25 mg twice a
week up to a dosage of 1 mg
twice a week according to the
patient’s serum prolactin level
Effective hypnotic dose: between
0.15 mg/kg and 0.30 mg/kg; doses
of 0.04 – 0.05mg/kg per h for
hypercortisolemia patients [30]
1 × 200 mg q.d. Daily dose: from 250 mg
to 6 g; 6 four-hourly doses
of 15 mg/kg, with a minimum
dose of 250 mg5
Dosage form Tablet Tablet Solution Tablet Capsule
Human AUC at the
clinical dose



















Table 3 Clinical pharmacokinetic profiles of medicines used for the treatment of hypercortisolism (Continued)
Mifepristone Mitotane Pasireotide Temozolomide
Trade name;
sponsoring company
Corluxin; HRA Pharma Lysodren; HRA Pharma Signifor; Novartis Temodal; Merck Sharp & Dohme
European birth date August 25, 1999 April 28, 2004 April 24, 2012 January 26, 1999
Cancer indication No Adrenocortical carcinoma No Glioblastoma
Cmax (μg/mL) 1.98 13.06 [31] N/A 13.97 [32]
tmax (h) 1.0 - 2.0 3.7
6 [31] 0.25 - 0.5 0.5 – 1.5
Bioavailability (oral, %) 69 absolute by lower
dose; higher dose 40








1.47 ± 0.25 [33] N/A Vz/F >100 Liter 0.397 [32]






Plasma half-life (h) 90 18 - 159 days ~12 1.8
Plasma protein binding
(%)
98 N/A 88 10 - 20
Empirical formula
(formula weight g/mol)
C29H35NO2 (429.6) C14H10Cl4 (320.0) C59H67N9O9 (1046.2) C6H6N6O2 (194.2)
Mechanism of action Competitive progesterone
receptor antagonist
Precise mechanism of action is
not known, but an adrenal
inhibition is suspected
Binding to four of five
somatostatin receptors;
(SSTR-1,-2,-3,-5) [34]
After poisoning of TMZ to active




600 mg Patients are titrated to reach
14 - 20 mg/L plasma concentration
starting with 2 - 3 g daily
0.6 mg b.i.d. (0.3 or 0.9 mg
dose adaption)8
Initially 200 mg/m2 daily
(pretreated patients:
150 mg/m2 daily)
Dosage form Tablet Tablet Subcutaneous injection Capsule
Human AUC at the
clinical dose
0.67 ± 0.21 μmol/l*h/mg9
[35]
N/A 54.1 ± 7.0 ng*h/mL10 [36] 33.2 μg*h/mL12 [32]
Abbreviations: AUC, area under the curve; b.i.d., twice daily; Cmax, maximal plasma concentration; q.d., every day; tmax, time after administration when Cmax is reached;
1500 mg; 2750 mg administration; 3n = 12, dose = 0.5 mg;
4in-vitro study with concentrations of 0.1 - 10 ng/ml; 5pediatric population; 6measured in dogs, 50 mg/kg, tablets in food; 7200 mg/m2; 8also available as long-acting release formulation in the strengths 20, 40, 60 mg;
9AUC0-inf;
10AUC0–24 h: 600 μg q.d. (n = 11);
1130 mg single dose in 24 healthy volunteers; 12AUC0–24 h; source of information: SmPCs of the corresponding medicines unless otherwise indicated (if not licensed for
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Ketoconazole originally was developed as an anti-fungal
medicine. In fact, it was one of the first orally bioavail-
able systemic anti-mycotic drugs but is also used locally.
Chemically it belongs to the first-generation imidazole anti-
fungal drugs (in contrast to triazols). Due to its hepatotoxic
properties, oral formulations of Ketoconazole are no longer
marketed as anti-fungal medicines as recommended by the
European Medicines Agency (EMA) after the Committee
for Medicinal Products for Human Use (CHMP) concluded
that the risk of liver injury is greater than the benefits in
treating fungal infections [60]. In fungi it mechanistically
acts as an ergosterole synthesis inhibitor by blocking vari-
ous CYP-dependent enzymes, thereby explaining both,
its hepatotoxic side-effects and its efficacy in Cushing’s
treatment: Steroidogenesis in the zona fasciculata of
the adrenal cortex mainly depends on CYP enzymes [61].
At lower doses, C17-20-lyase and 17-α-hydroxylase are
inhibited in both the testicular and adrenal glands. In
contrast, cholesterol side-chain cleavage enzymes and
11-β-hydroxylase are inhibited only at higher doses.
However, a negative benefit-risk-ratio for one indication
(anti-fungal) where alternatives exist does not imperatively
mean this also accounts for other indications (Cushing).
EMAs safety concern was due to severe hepatic injury but
the incidence was only 1 in 15000 cases [62], thus, benefit
risk might be different in a disease with high mortality
and less alternatives compared to the anti-fungal indica-
tion. Currently, Ketoconazole is used off-label in CS,
however, marketing authorization applications (MAAs)
are underway to change this unsatisfactory status. Thus,
future will tell whether Ketoconazole has a positive
benefit-risk ratio in CS and currently no final judgment
can be made. Ketoconazole may have clinical benefit in
CS patients with hyperandrogenic symptoms as it also
inhibits steroidogenesis of androgens (for instance in the
testes). The occurrence of hirsutism with Metyrapone
treatment in women may lead a clinician to choose
Ketoconazole in this case or may lead to a combination
therapy of Metyrapone and Ketoconazole. Some patients
even may require combination of both to achieve control
of CS. The dose of Ketoconazole used as monotherapy
in patients with CD ranges from 200 mg to 1200 mg
per day [63].
Metyrapone
Metyrapone (Metopirone®) is only registered in four
European countries (France, United Kingdom, the
Netherlands, and Ireland) through national procedures.
From the chemical structure, Metyrapone is a very simple
molecule displaying no stereochemistry (2-methyl-1,2-di
(pyridin-3-yl)propan-1-one). The drug is very old as it was
introduced into the pharmacological armamentarium in
the late 50ties of the last century. Thus, in most countries,it was not licensed in a modern way based on careful
assessment of quality, safety, and efficacy, but registered
and this is the reason why evidence whether Metyrapone
is a worthy option in the treatment of CS is rather low.
Most publications on the clinical use of Metyrapone are
case studies or case series, eventually very small, non-
controlled studies. Thus, licensing status is very different
among ICH (International Conference on Harmonisation
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use) countries. Metyrapone is more
frequently used in the UK in Ireland, while it is not even
licensed in Germany, Italy or Spain (to name just a few).
Metyrapone is an inhibitor of 11-β-hydroxylase thereby
inhibiting endogenous cortisol synthesis. In return, ACTH
synthesis is triggered, and this forms the basis for Metyra-
pone functional test in diagnosis of a properly functioning
hypothalamic-pituitary-adrenal (HPA) axis. However, the
substance is not listed in current diagnosis guidelines for
CS. According to current medicinal guidelines, diagnosis
of hypercortisolism (irrespective of its origin) is performed
according to the following scheme:
1. Complete blood count including serum electrolytes,
blood sugar etc.
2. UFC from 24 h-urine sampling and circadian profile
of plasma cortisol, plasma ACTH,




4. After endocrine diagnostic tests: magnetic resonance
imaging (MRI), ultra-sound, computer tomography
(CT) and other localization diagnostics
This diagnosis flow-scheme also is reflected in current
international text books [64] and for instance in the clinical
practice guidelines of the endocrine society [65]:
“After excluding exogenous glucocorticoid use, we
recommend testing for Cushing’s syndrome in patients
with multiple and progressive features compatible with
the syndrome, particularly those with a high
discriminatory value, and patients with adrenal
incidentaloma. We recommend initial use of one
test with high diagnostic accuracy (urine cortisol, late
night salivary cortisol, 1 mg overnight or 2 mg 48-h
dexamethasone suppression test). We recommend that
patients with an abnormal result see an endocrinologist
and undergo a second test, either one of the above or, in
some cases, a serum midnight cortisol or
dexamethasone-CRH test.”
Metyrapone, thus, is an excellent example for national
traditions determining clinical management of rare dis-
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because of the heterogeneity of the patients’ population
especially in regard to their co-morbidities. Consequently,
no (national or international) medicinal guidelines or
treatment algorithms of high evidence for management
of CS exist. A consensus statement on ACTH-dependent
CS published in 2008 by Biller et al. emphasized clinical
management of CS as a multi-disciplinary approach on an
individualized basis [66].
Despite its efficacy in lowering cortisol blood levels,
Metyrapone is not constantly effective and therefore
does not cover the entire CS-population. Clinical and/or
biochemical improvements can be achieved in 60 to 80%
of patients and are usually associated with improvements
in symptoms. In general, Metyrapone appeared to be
well tolerated, but may sometimes lead to an accumula-
tion of androgens in women during long-term treatment
(hirsutism).
Mifepristone
Mifepristone (experimental name RU-486) originally was
developed as the so-called “abortion pill”. Chemically it
is an all-trans steroid substituted at positions 11 and 17.
Mechanistically, it is an antagonist at the progesterone
receptor (PR), thereby explaining its acute abortive effect.
It also shows antagonistic activity at the glucocorticoid
receptor (GR) with a higher affinity than Dexamethasone.
Thus, unlike other agents, Mifepristone does not decrease
cortisol synthesis but directly antagonizes its effects. There-
fore, it is intuitive that patients dosed with Mifepristone
can hardly be diagnosed by serum cortisol measurements
as they remain unchanged. Mifepristone is not approved in
the indication CS. Side effects include decreased plasma
potassium levels with a potential for heart conduction
abnormalities, vaginal bleeding, and endometrial thick-
ening (not surprising for a progesterone antagonist).
Notions on Mifepristone
Apart from the fact that everyone knows it as an abortion
pill, it must not be forgotten that Mifepristone originally
was developed as an anti-glucocorticoid. Soon afterwards,
it was found to block PRs intrinsic activity. Due to its
pronounced cortisol-blocking effect, new generation
antiprogestins were developed aiming at reducing anti-
glucocorticoid activity while maintaining anti-progesterone
activity (i.e. ORG-31710, CDB-2914, CDB-4124). However,
only Mifepristone has been licensed by US Food and Drug
Administration (FDA) to terminate early pregnancy (work-
ing as an antiprogestin) or ameliorating the hyperglycemia
in CS-patients [67]. In contrast, other PR antagonists like
ulipristal and proellex are currently investigated for their
potential to alleviate symptoms in endometriosis and
uterine fibroids, thereby approaching indications like other
hormone ablative medicines (i.e. GnRH analogues) [68].Interestingly, Tieszen et al. investigated the potential
of PR antagonists, to inhibit the growth of cells from
endocrine related cancers (i.e. ovarian-, breast-, and
prostate cancer cells), expressing different sets of hor-
mone receptors. The authors found, that all cancer cells
were inhibited in growth irrespective of their PR status,
as there are: MCF-7 breast cancer cells carrying PR,
MDA-MB- 231 breast cancer cells with no PR expression,
PR negative and androgen receptor positive LNCaP
prostate cancer cells, and PR negative androgen receptor
positive PC3 prostate cancer cells are all inhibited by
mifepristone with similar potency [69].
However, all cell lines under investigation in this study
express GR and derivatives of mifepristone with lower
GR affinity are less effective. Therefore, it can be concluded
that GR action might contribute to anti-tumor effects of PR
antagonists. Thus, PRs may not be required for the in-
hibition of cancer growth triggered by Mifepristone. In
addition, it has been shown by another group, that Mife-
pristone blocked the growth of estrogen receptor negative
and PR negative MDA-MB-231 breast cancer cells [70].
Mitotane
Mitotane is another unusual drug used in certain very
rare cases of CS. Mitotane (Lysodren®) is authorized only
for symptomatic treatment of advanced (very rare) adrenal
cortical carcinoma (ACC). Chemically it is an ortho-
derivative of the long-term known insecticide DDT
(dichloro-diphenyl-trichloroethane), the bis-trans-form
of the molecule. Its biochemical mechanism is not yet
fully understood, but inhibition of side-chain cleavage
of cholesterol (a decisive step in endogenous steroido-
genesis) seems to play a role as well as blockade of 3-
β-hydroxysteroid-deshydrogenase [71]. Like its mother
substance DDT Mitotane also accumulates in adipose
tissue, which might then be entailed with longer half-life.
Especially in Cushing’s patients this is of particular con-
cern, as these patients usually present with higher fat mass
compared to age-adjusted matched population. Therefore,
it usually takes weeks until complete efficacy is reached.
In the current SmPC it is even mentioned that 3 - 5
months can be assumed until the intended plasma level of
14 - 20 mg/L is reached. This window should be reached
(titrated) by monitoring patients’ blood levels. Thus, Mito-
tane fulfills the requirements of a Narrow Therapeutic
Index Drug (NTID) according to the FDA definition.
Mitotane has an orphan designation and, thus, the pivotal
registration trial was performed in 177 patients only
showing an increase in recurrence-free interval after
radical surgery followed by Mitotane compared to surgery
alone [72]. Grade 3 side effects were mainly neurologic
(confusion, ataxia, vertigo) or biochemical (elevated γ-
glutamyltransferase). Thus, Mitotane might be of clinical
benefit in some patients, adjuvant to radical surgery.
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Pasireotide mechanistically is a somatostatin-analogue
(SSA). SSAs are the first-line medical treatment in GH-
secreting adenomas (with the clinical manifestation of
acromegaly). Currently two different molecular entities,
octreotide (Sandostatin®) and lanreotide (Somatuline®),
are marketed. Octreotide, which was licensed 25 years
ago, is available as a short-acting subcutaneous formu-
lation for twice-daily administration, and a long-acting
(LAR) microsphere preparation administered by intra
muscular injection every 4 weeks. Lanreotide is avail-
able in a microsphere formulation (sustained release)
and a high-concentrate aqueous solution (Autogel).
From clinical safety point of view SSA side effects
include gallstones and gastrointestinal affection (diar-
rhea, nausea, abdominal pain). According to the route
of administration injection site reactions (pain, swelling)
have also been reported.
Pasireotide (experimental name SOM230) itself is a
cyclic hexapeptide and was licensed via the central route
in Europe in 2012 as first-line pharmacological therapy
option. The European Public Assessment Report (EPAR)
is dated June 1st 2012 [73].
Endogenous somatostatin is a peptide hormone widely
distributed in the endocrine system. Somatostatin action
is mediated through five different SSTR subtypes (SSTR-
1-SSTR-5). SSTRs belong to the superfamily of tripartite
G-protein coupled receptors. They are expressed over the
whole body in various tissues, with cells from different
tissues expressing different receptor subtypes at different
densities. The physiological actions of somatostatin are
numerous. It is an inhibitory protein of endocrine secre-
tion of various organs, including the pituitary, pancreas,
gastrointestinal tract, thyroid, kidney, and adrenal
glands. Among others, it inhibits gallbladder contract-
ility and bile flow, and stimulates gastrointestinal
water and electrolyte absorption. Pasireotide has a
slightly different SSTR binding profile than the first-
generation SSAs Octreotide and Lanreotide, with high
affinity to four of the five receptors (SSTR-1, −2, −3
and −5). Compared to Octreotide the binding affinity
of Pasireotide is 30 - 40 times greater for SSTR-1 and
SSTR-5 and 5 times greater for SSTR-3, whereas the
affinity for SSTR-2 is comparable.
In general, medicines for the treatment of CS (i.e.
Mifepristone, Ketoconazole) are not selective and initially
were not developed for the treatment of CS. In contrast,
Pasireotide exhibits at least a subtype-prevalence for
subtype-5 of the SSTR in the pituitary gland. SSTR-5
prevalently is expressed at the surface of ACTH secreting
cells, thus showing at least partial specificity in lowering
excessive cortisol blood levels. Therefore, first-line phar-
macological therapy is Pasireotide injection (usually while
definitive therapy is awaited).In addition, the basis of the centralized approval for
Pasireotide was a clinical development program consist-
ing (only regarding patients) of
1. a 22-patient phase II study reviewed in [74]
2. a randomized-dose, double-blinded pivotal phase III
study [75].
The study design was as follows:
162 patients with Cushing’s disease were randomized
(double-blind) to pasireotide 600 μg (n = 82) or 900 μg
(n = 80) sc bid. After 3mo, patients with UFC > 2 ×ULN
(ULN: 145 nmol/24 h) or UFC > baseline were unblinded
and the dose increased by 300 μg bid. All others
continued on the same double-blind dose to 6mo. Months
6–12 were open-label with dose titration performed when
needed. Primary endpoint: UFC≤ULN at 6mo without
dose up-titration from the randomized dose.
However, it should be noticed that Pasireotide is indi-
cated only in a subgroup of CD-patients and shows
satisfactory efficacy only in ~ 30% of patients. Side effects
with this agent are similar to those of other SSAs.
Hyperglycemia-associated side-effects are of particular
concern in CS patients and were reported in 73% of
patients in the pivotal study.
Temozolomide
Temozolomide (Temodal®) is licensed for Grade III and
IV glioblastoma multiforme concomitant to radiotherapy
[76]. Temozolomide is an orally bioavailable, centrally
active alkylating agent. Following a systematic review
from 2012 up to now, 46 cases of adenohypophysial
tumors are published in Medline that were treated with
Temozolomide (30 adenomas, 16 carcinomas). 60% of the
adenomas and 69% of carcinomas responded favorably to
treatment [77]. Thus, in (rare) cases of highly aggressive
growing macroademomas or pituitary carcinomas Temo-
zolomide might be an option.
Trilostane (only in veterinary use)
Chemically Trilostane is a 2-cyano-4,5-epoxy-steroid.
Trilostane reversibly suppresses adrenal function. From
its molecular mechanism of action it inhibits cortisol
biosynthesis by prevalently blocking 3-β-hydroxysteroide-
dehydrogenase. This, however, does not only block
cortisol- and corticosteron-synthesis, but also biosynthesis
of aldosterone. Thus, Trilostane un-specifically blocks
both, glucocorticoids and mineralocorticoids. High doses
are reported to even block gonadal steroidogenesis.
However, Trilostane is not used as human medicine; its
only indication is CS in dogs, irrespective whether CS
derives from pituitary or adrenal cortisol-overproduction.
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the medical treatment of choice for dogs with adrenal-
dependent hyperadrenocorticism [78].
Therapy of Cushing’s syndrome in children
First of all, in the pediatric population no final conclusion
can be drawn on any of the medicines under investigation
due to lack of pivotal evidence. This is best reflected by
the fact that the EMA accepted a waiver for clinical data
from pediatric patients for centrally approved Pasireotide
(a so-called “PIP-Waiver”; PIP, pediatric investigation
plan). Throughout the SmPCs it is mentioned that only
limited evidence is available for children and, thus, the re-
spective medicine is not recommended for use in children.
However, in those drugs used off-label even this is based
on other indications. There is only one exemption from
the rule; for Metyrapone the following can be read in the
SmPC: “In children the dosage should be 15 mg/kg body-
weight, with a minimum dose of 250 mg every 4 hours
for 6 doses.” However, even for Metyrapone evidence in
children is very low (15 documented cases) [2,79,80].
Co-medication for symptomatic therapy
Clinical management of co-morbidities of CS is a com-
plex challenge. Post-surgery management of CS patients
is tri-phasic. Ragnarsson and Johannsson summarized
systemic therapy while awaiting success of surgery (or
radiotherapy) [3].
Usually supportive therapy of CS co-morbidities is by in-
dividual therapy depending on clinical presentation of the
patient. Certain hazardous (life-threatening) symptoms are
treated on a case-by-case decision according to medicinal
guidelines of the respective symptoms. The following
medicinal guidelines may serve as examples for clinical
management of most hazardous co-morbidities:
➢ Therapy of type 2 diabetes mellitus [81] - evidence
level S3
➢ Prophylaxis, diagnosis, and treatment of
osteoporosis [82] - evidence level S3
➢ Depressive disorder [83] - evidence level S3
➢ Arterial hypertension [84] - evidence level S2
Conclusion
CS can arise from different pathological conditions ranging
from benign pituitary adenomas to adrenal carcinomas or
ectopic cortisol secretion. Thus, various drugs with differ-
ent target structures and mechanisms of action are used in
systemic therapy of CS comprising somatostatin-analogues,
cortisol synthesis inhibitors, receptor antagonists and
unusual substances like Temozolomide and Mitotane for
certain very rare conditions. Some mechanisms of action
are well known (Pasireotide, Ketoconazole) others are not
fully understood (Mitotane).These drugs differ in terms ofsafety profile, route of administration, and indications
considerably. In addition, safety profiles differ considerably
and become hardly predictable, if combinations are
needed due to insufficient clinical control of CS by only
one substance. Many of these substances are used off-
label and constitute an ultima ratio approach after failure
of preceding therapy options. Thus, clinical and/or at least
epidemiological data will be needed to finally judge on
safety and efficacy in regard of a debilitating underlying
disease.Search strategy
Recherché of clinical PK-parameter and special populations
i) SmPCs as published on the heads of medicines agencies
(HMA) homepage (http://mri.medagencies.org/Human/)
were accessed in March and June 2014. Section 5.2
(Pharmacokinetics) of SmPCs systematically was searched
for PK-parameters.
ii) A search in PubMed/Medline was performed in March
and June 2014 using the international non-proprietary
name (INN) of the respective medicinal product combined
with the terms “cushing” and “indication” as well as “cush-
ing” and “pediatric”. PubMed recherché was restricted by
searching only in clinical trials.Safety profile assessment
SmPCs of currently marketed medicinal products were
accessed (if not licensed for treatment of CS, then in other
indication; i.e. Ketoconazole, Etomidate, Temozolomide,
and Pioglitazone). If not marketed any more (Aminoglu-
tethimide) the last approved SmPC was used except for
Trilostane, were veterinary SmPC of Swissmedic was used.
Side-effects were categorized by frequency for preferred
terms (PT) of the systems organ class (SOC) system (XX=
common, very common; X = rare, uncommon; not known).
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